Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Vaccines in India

被引:14
作者
Amdekar, Yeshwant K. [1 ]
Lalwani, Sanjay K. [2 ]
Bavdekar, Ashish [3 ]
Balasubramanian, S. [4 ,5 ]
Chhatwal, Jugesh [6 ]
Bhat, Swarna Rekha [7 ]
Verghese, Valsan Philip [8 ]
Tansey, Susan P. [9 ]
Gadgil, Durga [10 ]
Jiang, Qin [11 ]
Pride, Michael [12 ]
Emini, Emilio A. [11 ]
Gruber, William C. [12 ]
Scott, Daniel A. [12 ]
机构
[1] Jaslok Hosp & Res Ctr, Bombay, Maharashtra, India
[2] Bharati Vidyapeeth Univ, Coll Med, Pune, Maharashtra, India
[3] KEM Hosp Res Ctr, Dept Pediat, Pune, Maharashtra, India
[4] Kanchi Kamakoti CHILDS Trust Hosp, Madras, Tamil Nadu, India
[5] CHILDS Trust Med Res Fdn, Madras, Tamil Nadu, India
[6] Christian Med Coll & Hosp, Ludhiana, Punjab, India
[7] St Johns Med Coll, Dept Pediat, Bangalore, Karnataka, India
[8] Christian Med Coll & Hosp, Dept Child Hlth, Vellore, Tamil Nadu, India
[9] Pfizer Inc, Maidenhead, Berks, England
[10] Pfizer Inc, Pharmaceut India Pvt Ltd, Bombay, Maharashtra, India
[11] Pfizer Inc, Collegeville, PA USA
[12] Pfizer Inc, Pearl River, NY USA
关键词
immunogenicity; pneumococcal vaccine; pediatric; safety; STREPTOCOCCUS-PNEUMONIAE; PEDIATRIC VACCINATIONS; CROSS-REACTIVITY; CHILDREN YOUNGER; POLYSACCHARIDES; EFFICACY; SERIES; AGE;
D O I
10.1097/INF.0b013e31827b478d
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The childhood burden of disease attributable to Streptococcus pneumoniae is particularly high in India. The immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) were compared with 7-valent pneumococcal conjugate vaccine (PCV7) in a randomized, active-controlled, double-blind trial conducted at 12 sites in India. Methods: Healthy infants received PCV13 or PCV7 at 6, 10, and 14 weeks of age (infant series) and at 12 months of age (toddler dose), along with routine pediatric vaccinations. Immunoglobulin G responses against the 13 pneumococcal serotypes were evaluated 1 month after the infant series and after the toddler dose. Pertussis and poliomyelitis immune responses were assessed 1 month after the infant series. Safety and tolerability also were assessed. Results: The immunogenicity results for the 7 common serotypes and the concomitant vaccines (whole-cell pertussis and oral poliovirus) were similar for subjects receiving PCV13 and subjects receiving PCV7. Immune responses to the 6 additional serotypes were higher in the PCV13 group compared with the PCV7 group. PCV13 and PCV7 had similar safety and tolerability profiles. Conclusions: PCV13 has immunogenicity similar to PCV7 in response to the 7 common serotypes, and has generally higher immunogenicity in response to the 6 additional serotypes. PCV13 may provide added protection against pneumococcal disease caused by the additional 6 serotypes and does not interfere with immune responses to whole-cell pertussis and oral poliovirus vaccines. PCV13 has an acceptable safety profile in both infants and toddlers, comparable with that of PCV7.
引用
收藏
页码:509 / 516
页数:8
相关论文
共 25 条
[11]  
Kanungo R, 2001, INDIAN J MED RES, V114, P127
[12]   Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany [J].
Kieninger, Dorothee M. ;
Kueper, Kathrin ;
Steul, Katrin ;
Juergens, Christine ;
Ahlers, Norbert ;
Baker, Sherryl ;
Jansen, Kathrin U. ;
Devlin, Carmel ;
Gruber, William C. ;
Emini, Emilio A. ;
Scott, Daniel A. .
VACCINE, 2010, 28 (25) :4192-4203
[13]   Carriage of antibiotic-resistant pneumococci among Asian children: A multinational surveillance by the Asian network for surveillance of resistant pathogens (ANSORP) [J].
Lee, NY ;
Song, JH ;
Kim, S ;
Peck, KR ;
Ahn, KM ;
Lee, SI ;
Yang, YH ;
Li, J ;
Chongthaleong, A ;
Tiengrim, S ;
Aswapokee, N ;
Lin, TY ;
Wu, JL ;
Chiu, CH ;
Lalitha, MK ;
Thomas, K ;
Cherian, T ;
Perera, J ;
Yee, TT ;
Jamal, F ;
Warsa, UC ;
Van, PH ;
Carlos, CC ;
Shibl, AM ;
Jacobs, MR ;
Appelbaum, PC .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (10) :1463-1469
[14]  
Levine OS, 2007, INDIAN PEDIATR, V44, P491
[15]  
Mathew JL, 2008, INDIAN PEDIATR, V45, P160
[16]  
Mishra A, 2008, INDIAN PEDIATR, V45, P161
[17]   Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates [J].
O'Brien, Katherine L. ;
Wolfson, Lara J. ;
Watt, James P. ;
Henkle, Emily ;
Deloria-Knoll, Maria ;
McCall, Natalie ;
Lee, Ellen ;
Mulholland, Kim ;
Levine, Orin S. ;
Cherian, Thomas .
LANCET, 2009, 374 (9693) :893-902
[18]   Epidemiology and etiology of childhood pneumonia [J].
Rudan, Igor ;
Boschi-Pinto, Cynthia ;
Biloglav, Zrinka ;
Mulholland, Kim ;
Campbell, Harry .
BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2008, 86 (05) :408-416
[19]   Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age A Double-blind Randomized Active-controlled Trial [J].
Snape, Matthew D. ;
Klinger, Chaam L. ;
Daniels, Elvis D. ;
John, Tessa M. ;
Layton, Helen ;
Rollinson, Llinos ;
Pestridge, Sarah ;
Dymond, Sandra ;
Galiza, Eva ;
Tansey, Susan ;
Scott, Daniel A. ;
Baker, Sherryl A. ;
Jones, Thomas R. ;
Yu, Ly-Mee ;
Gruber, William C. ;
Emini, Emilio A. ;
Faust, Saul N. ;
Finn, Adam ;
Heath, Paul T. ;
Pollard, Andrew J. .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (12) :E80-E90
[20]   Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India [J].
Thomas, K ;
Lalitha, MK ;
Steinhoff, MC ;
Arora, NK ;
Ratan, A ;
Das, B ;
Awasthi, SK ;
Misra, PK ;
Amita, J ;
Daivanayagam, R ;
Manjula, P ;
Jain, D ;
Agarwal, V ;
Ravindran, P ;
Cherian, T ;
Raghupathy, P ;
Moses, P ;
Jesudason, MV ;
Brahmadathan, KN ;
Jayseelan, L ;
John, TJ .
LANCET, 1999, 353 (9160) :1216-1221